Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Just how independent is Genentech?
Questions continue to swirl as the unit mulls another oncology makeover.
Pfizer takes on Merck in a new checkpoint
Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.
Fresh questions over DLL3
Five years after AbbVie pulled the plug on rova-T, DLL3 comes under the spotlight again.
